Istituto Clinico Humanitas

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 3 drugs with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

1 drugs in development

Preclinical1

By Therapeutic Area

top 1

Oncology

1100%

R&D Momentum

47/100

Pipeline Velocity

22/100

Trial Completion Rate

86/100

Pipeline Concentration

100/100

Pipeline Freshness

34/100

Activity

Recent Activity

Last 14 days

Oct 31, 2026

Recruiting

Saving by Artificial Intelligence for Virtual Endoscopy Biopsy Artificial Intelligence to Implement Cost-saving Strategies for Colonoscopy Screening Based on in Vivo Prediction of Polyp Histology

Earlier

Aug 28, 2026TrialPhoton-counting CT Scan vs Standard HRCT Scan in the Identification of Idiopathic Pulmonary Fibrosis

Jul 29, 2026TrialPhoton-Counting Computed Tomography-Based Urethral Visualization Without Catheterization for Radiotherapy Planning: A Prospective Pilot Study Under ANTHEM

Jul 8, 2026TrialAdvanced Respiratory Monitoring for Safer Mechanical Ventilation in Patients Without Respiratory Failure

Jun 26, 2026TrialIntra-operative Hypotension and Post-operative Lactate Level After Pancreatic-duodenectomy. A Prospective Multicenter Observational Study

Jun 26, 2026TrialRIght VEntricle Response to Major Lung Resection in VATS and Robotic Surgery (the RIVER-2 Study)

Jun 25, 2026TrialThe Impact of Fast Antimicrobial Sensitivity Testing Tools on Stewardship Antibiotic and Clinical Outcome: a Randomized Clinical Trial Within an Adaptive Platform Trial for Patients With Bloodstream Infections

Mar 25, 2026TrialMulticenter Retrospective International Study to Evaluate Outcomes and Safety of Patients Undergoing ERCP Using a Single-use Cholangioscope (SpyGlass DS II) and Single-use Duodenoscope (Exalt) - The MESE Study

4 more events

Feb 9, 2026FDAReglan — REGLAN

Dec 16, 2024FDAArimidex — ARIMIDEX

Jun 16, 2023TrialStudy of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure

Dec 13, 2022TrialEvaluation Study of the Intestinal Microbiota and Quality of Life in Patients Suffering From IBS Treated With Bifidice

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

6 patent groups across drugs · Source: FDA Orange Book

DrugExpires

VeregenOct 2, 2026 Reglan5 patentsDec 22, 2029 ReglanMay 16, 2030 ReglanNov 17, 2038 ActhJul 18, 2041 Acth6 patentsOct 27, 2043

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Oncology

Prostate Cancer

immune evaluation

Oncology

Prostate Cancer

immune evaluationPreclinical

Regulatory

Regulatory Timeline

20102 events

FDANov 18

Reglan — REGLAN

Application NDA017854

FDASep 15

Casodex — CASODEX

Application NDA020498

20113 events

FDASep 22

Reglan — REGLAN

Application NDA017854

FDAAug 2

Reglan — REGLAN

Application NDA017854

FDAApr 18

Arimidex — ARIMIDEX

Application NDA020541

20132 events

FDASep 12

Casodex — CASODEX

Application NDA020498

FDAMay 1

Arimidex — ARIMIDEX

Application NDA020541

20141 event

FDAMay 2

Arimidex — ARIMIDEX

Application NDA020541

20154 events

FDAJun 15

Reglan — REGLAN

Application NDA017854

FDAApr 17

Reglan — REGLAN

Application NDA017854

FDAFeb 27

Casodex — CASODEX

Application NDA020498

FDAJan 12

Reglan — REGLAN

Application NDA017854

20173 events

FDANov 1

Casodex — CASODEX

Application NDA020498

FDAAug 29

Reglan — REGLAN

Application NDA017854

FDAMar 17

Casodex — CASODEX

Application NDA020498

20181 event

FDADec 13

Arimidex — ARIMIDEX

Application NDA020541

20202 events

FDAJun 19

Reglan — GIMOTI

Application NDA209388 (NDA)

FDAJun 19

Reglan — GIMOTI

Application NDA209388 (NDA)

20241 event

FDADec 16

Arimidex — ARIMIDEX

Application NDA020541

20261 event

FDAFeb 9

Reglan — REGLAN

Application NDA017854

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)